EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Akeso's enterprise value is HK$40,585 Mil.
Akeso's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$4,951 Mil. Therefore, Akeso's EV-to-Revenue for today is 8.20.
The historical rank and industry rank for Akeso's EV-to-Revenue or its related term are showing as below:
HKSE:09926'
s EV-to-Revenue Range Over the Past 10 Years
Min: 6.29 Med: 68.37 Max: 618.39
Current: 8.2
During the past 6 years, the highest EV-to-Revenue of Akeso was 618.39. The lowest was 6.29. And the median was 68.37.
HKSE:09926's EV-to-Revenue is ranked worse than 51.11% of 1037
companies
in the Biotechnology industry
Industry Median: 7.95
vs HKSE:09926: 8.20
As of today (2024-05-14), Akeso's stock price is HK$49.20.
Akeso's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$5.91. Therefore, Akeso's PS Ratio for today is 8.32.
Akeso EV-to-Revenue Historical Data
The historical data trend for Akeso's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Akeso's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akeso's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akeso's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Akeso's EV-to-Revenue falls into.
Akeso's current Enterprise Value is HK$40,585 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Akeso's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$4,951 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akeso's share price for today is HK$49.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$5.91.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akeso EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Akeso's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09926 has been successfully added to your 